RNS Number : 3950H
NetScientific PLC
19 May 2014

NetScientific announces research agreement with Harvard University



NetScientific plc (AIM:NSCI, 'NetScientific' or 'The Group'), the biomedical and healthcare technology investment group, is pleased to announce that Vortex, its Palo Alto based spinout, has signed an agreement with the Rowland Institute at Harvard University.  Under the research agreement, the Rowland Institute will explore the use of circulating tumor cell (CTC) technology in a study to analyze improvements in patient diagnosis and prognosis that may be possible from capturing live CTCs in blood samples. If successful, the company believes that, once the processes are fully developed, they could transform the way medical practitioners select drug treatments for patients and how new classes of anticancer therapeutics are developed. 


Vortex's technology enables direct selection and capture of live CTCs from whole blood.  Cells can be captured and held within the Vortex microfluidic chip for enumeration and analysis and work at the Rowland Institute will focus on effecting and evaluating potential drug treatment of live CTCs within the Vortex chip.



For further information, please contact:


  Liberum (Nomad & Broker)

  Chris Bowman / Christopher Britton / Thomas Bective

Tel: 020 3100 2000

  Bell Pottinger

  Daniel de Belder

Tel: 020 7861 3232


Company website:www.netscientific.net




NetScientific is a healthcare and life sciences company with global reach that funds and develops technologies that offer transformative benefits to peoples' lives and society through improved diagnosis, prognosis and treatment. The group is primarily focused on identifying and developing cutting edge technologies with applications in several: (i) cardiovascular; (ii) liver; (iii) cancer; (iv) metabolic; and (v) digital health.



Vortex Biosciences, Inc.(Vortex) is developing a novel liquid biopsy technology that could revolutionise cancer diagnosis and monitoring.


Based in Palo Alto, California, and formed in 2010, Vortex has exclusive, world-wide rights to all technologies developed in connection with a project from a laboratory based at a leading University in the USA.


NetScientific's cancer diagnostics company is developing blood test cancer diagnostics by detecting, quantifying and harvesting Circulating Tumor Cells.  These live CTCs offer important possibilities in advanced therapeutics and personalised medicine. 



This information is provided by RNS
The company news service from the London Stock Exchange